- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01721785
Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Limburg
-
Heerlen, Limburg, Nederländerna, 6401 CX
- Atrium medisch centrum
-
Maastricht, Limburg, Nederländerna, 6202 AZ
- Maastricht University Medical Center
-
Sittard-Geleen, Limburg, Nederländerna, 6130 MB
- Orbis Medisch Centrum
-
Venlo, Limburg, Nederländerna, 5912 BL
- VieCuri Medisch Centrum
-
-
Noord-Brabant
-
's Hertogenbosch, Noord-Brabant, Nederländerna, 5223 GZ
- Jeroen Bosch ziekenhuis
-
Breda, Noord-Brabant, Nederländerna, 4800 RL
- Amphia Ziekenhuis
-
Eindhoven, Noord-Brabant, Nederländerna, 5623 EJ
- Catharina Ziekenhuis
-
Veldhoven, Noord-Brabant, Nederländerna, 5500 MB
- Maxima Medisch Centrum
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Nederländerna, 1100 DD
- AMC
-
-
Overrijsel
-
Almelo, Overrijsel, Nederländerna, 7600 SZ
- ZGT
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Biopsy proven primary rectal cancer (≤15 cm from the anorectal verge as measured in MRI)
- Age > 18 years
- Written informed consent
Exclusion Criteria:
- Ineligibility to undergo MRI (claustrophobia, pacemaker, non-MR compatible surgical implants, metal fragments in the eye)
- Pregnancy
- Locally recurrent rectal cancer
- A history of severe allergy to contrast agents
- Ineligibility to receive gadofosveset contrast (history of contrast allergy, impaired kidney function with a Glomerular Filtration Rate <30 ml/min/1.73m2
- Incurable disease due to metastases or co-morbidity
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Primary staging group I
All patients will be treated according to standard practice of the concerning hospital. Patients in group I are patients that will be stratified for direct surgery (TME) or a short-course of radiotherapy (5x5 Gy) followed by immediate TME. Group I will undergo only a staging MRI, including gadofosveset-enhanced MRI. |
Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
Andra namn:
|
Restaging group II
All patients will be treated according to standard practice of the concerning hospital. Patients in group II are patients that will be stratified for a long course of chemoradiotherapy. Group II will undergo a staging MRI, a re-staging MRI and a optional sigmoidoscopy as part of restaging. MRI includes diffusion-weighted imaging and gadofosveset-enhanced MRI. |
Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Diagnostic performance of the techniques under investigation
Tidsram: 2 years
|
Techniques under investigation are diffusion-weighted imaging for tumour response assessment and gadofosveset-enhanced MRI for nodal assessment, compared to standard T2-weighted MRI.
|
2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
To determine the inter-observer agreement for the imaging techniques under investigation
Tidsram: 2 years
|
Detection of the differences between expert vs non-expert readers and general vs referral centres concerning diffusion-weighted imaging and gadofosveset-enhanced MRI.
|
2 years
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Regina Beets-Tan, Prof. MD., Radiology, MUMC
- Huvudutredare: Geerard Beets, Ass Prof. MD, Surgery, MUMC
- Studiestol: Doenja Lambregts, MD, Radiology, MUMC
- Studiestol: Monique Maas, MD, Radiology, MUMC
Publikationer och användbara länkar
Allmänna publikationer
- Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr, Suarez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010 Sep;11(9):835-44. doi: 10.1016/S1470-2045(10)70172-8. Epub 2010 Aug 6.
- Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, Gama-Rodrigues J. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006 Dec;10(10):1319-28; discussion 1328-9. doi: 10.1016/j.gassur.2006.09.005.
- Kim SH, Lee JM, Hong SH, Kim GH, Lee JY, Han JK, Choi BI. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology. 2009 Oct;253(1):116-25. doi: 10.1148/radiol.2532090027.
- Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef M, Leijtens JW, Hulsewe KW, Buijsen J, Beets GL. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011 Dec 10;29(35):4633-40. doi: 10.1200/JCO.2011.37.7176. Epub 2011 Nov 7.
- Yamashita T, Takahara T, Kwee TC, Kawada S, Horie T, Inomoto C, Hashida K, Yamamuro H, Myojin K, Luijten PR, Imai Y. Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment. Jpn J Radiol. 2011 Jan;29(1):25-32. doi: 10.1007/s11604-010-0513-2. Epub 2011 Jan 26.
- Lambregts DM, Beets GL, Maas M, Kessels AG, Bakers FC, Cappendijk VC, Engelen SM, Lahaye MJ, de Bruine AP, Lammering G, Leiner T, Verwoerd JL, Wildberger JE, Beets-Tan RG. Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. Ann Surg. 2011 Mar;253(3):539-45. doi: 10.1097/SLA.0b013e31820b01f1.
- Lahaye MJ, Engelen SM, Nelemans PJ, Beets GL, van de Velde CJ, van Engelshoven JM, Beets-Tan RG. Imaging for predicting the risk factors--the circumferential resection margin and nodal disease--of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR. 2005 Aug;26(4):259-68. doi: 10.1053/j.sult.2005.04.005.
- Herborn CU, Lauenstein TC, Vogt FM, Lauffer RB, Debatin JF, Ruehm SG. Interstitial MR lymphography with MS-325: characterization of normal and tumor-invaded lymph nodes in a rabbit model. AJR Am J Roentgenol. 2002 Dec;179(6):1567-72. doi: 10.2214/ajr.179.6.1791567.
- Kim SH, Lee JY, Lee JM, Han JK, Choi BI. Apparent diffusion coefficient for evaluating tumour response to neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Eur Radiol. 2011 May;21(5):987-95. doi: 10.1007/s00330-010-1989-y. Epub 2010 Oct 27.
- Lambregts DM, Vandecaveye V, Barbaro B, Bakers FC, Lambrecht M, Maas M, Haustermans K, Valentini V, Beets GL, Beets-Tan RG. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol. 2011 Aug;18(8):2224-31. doi: 10.1245/s10434-011-1607-5. Epub 2011 Feb 23.
- Curvo-Semedo L, Lambregts DM, Maas M, Thywissen T, Mehsen RT, Lammering G, Beets GL, Caseiro-Alves F, Beets-Tan RG. Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging. Radiology. 2011 Sep;260(3):734-43. doi: 10.1148/radiol.11102467. Epub 2011 Jun 14.
- Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010 Dec;53(12):1692-8. doi: 10.1007/DCR.0b013e3181f42b89.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 12-2-051
- 2012-002935-27 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Rektal neoplasmer
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Ooperbar malign neoplasm | Avancerad malign neoplasmFörenta staterna
-
Massachusetts General HospitalRekryteringMalign neoplasm | Benign neoplasmFörenta staterna
-
Institut BergoniéAvslutadMedium och Lower Rectal CancerFrankrike
-
King Faisal Specialist Hospital & Research CenterAvslutadEtt försök med preoperativ kemoradioterapi med capecitabin, strålning och cetuximab vid rektalcancerColon Rectal Cancer Duke Stage StagevalSaudiarabien
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMalign neoplasm | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeTrötthet | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Refraktär malign neoplasmFörenta staterna
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)AvslutadAvancerad malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
Kliniska prövningar på GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]
-
The First Affiliated Hospital with Nanjing Medical...Wu Jieping Medical FoundationAvslutad